Evidence map›Paper›PMID 24800655›Full record

ArticleExperimental eye research2014

Reversal of fibrosis by TGF-β3 in a 3D in vitro model.

D Karamichos, A E K Hutcheon, J D Zieske

Open access · greenAbstract read
In one paragraph

Article in Experimental eye research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
4.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 55 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. CD4iScience · 2023
    Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. The Role of TGF-β3 in Radiation Response.International journal of molecular sciences · 2023
    Review
  12. Article
  13. Article
  14. Article
  15. Corneal myofibroblasts and fibrosis.Experimental eye research · 2020
    Review
  16. Article
  17. Fibrosis: Shared Lessons From the Lens and Cornea.Anatomical record (Hoboken, N.J. : 2007) · 2020
    Review
  18. Article
  19. Corneal injury: Clinical and molecular aspects.Experimental eye research · 2019
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

D KaramichosSchepens Eye Research Institute/Massachusetts Eye and Ear and the Department of Ophthalmology, Harvard Medical School, 20 Staniford Street, Boston, MA, USA. Electronic address: dimitrios-karamichos@ouhsc.edu.
A E K HutcheonSchepens Eye Research Institute/Massachusetts Eye and Ear and the Department of Ophthalmology, Harvard Medical School, 20 Staniford Street, Boston, MA, USA. Electronic address: audrey_hutcheon@meei.harvard.edu.
J D ZieskeSchepens Eye Research Institute/Massachusetts Eye and Ear and the Department of Ophthalmology, Harvard Medical School, 20 Staniford Street, Boston, MA, USA. Electronic address: james_zieske@meei.harvard.edu.
Harvard University Press · USHarvard University · US

Funding

VISION RESEARCHP30EY003790 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI Patricia Ann D'Amore · 1985 to 2026
$25.5M
CORNEAL STROMAL-EPITHELIAL INTERACTIONS DURING REPAIRR01EY005665 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI Joseph B. Ciolino · 1985 to 2026
$14.4M
Transplantation of a self-assembled corneal substituteR01EY020886 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI KARAMICHOS, DIMITRIOS, ZIESKE, JAMES D · 2011 to 2014
$1.9M
NEI NIH HHS P30 EY003790NEI NIH HHS P30EY03790NEI NIH HHS R01 EY005665NEI NIH HHS R01EY005665NEI NIH HHS R01 EY020886NEI NIH HHS R01EY020886
6 · The paper itself

Abstract

Corneal scarring following moderate to severe injury is inevitable. Despite significant advancements in the field, current treatments following these types of injuries are limited, and often, the visual recovery is poor. One of the problems and limitations is that corneal wound healing is a complex process, involving corneal cells, extracellular matrix components and growth factors. Therefore, further understanding is required, along with new treatments and techniques to reduce or prevent corneal scarring following injury. Two isoforms of transforming growth factor-beta (TGF-β), TGF-β1 and -β3 (T1 and T3, respectively), are associated with corneal wound healing. T1 has been shown to drive the corneal keratocytes to differentiate into myofibroblasts; whereas, T3 has been found to inhibit fibrotic markers. In the current study, we examined whether the fibrotic characteristics expressed by human corneal fibroblasts (HCF) in our 3-dimensional (3D) construct following T1 stimulation could be reversed by introducing T3 to the in vitro system. To do this, HCF were isolated and cultured in 10% serum, and when they reached confluence, the cells were stimulated with a stable Vitamin C (VitC) derivative for 4 weeks, which allowed them to secrete a self-assembled matrix. Three conditions were tested: (1) CONTROL: 10% serum (S) only, (2) T1: 10%S + T1, or (3) Rescue: 10%S + T1 for two weeks and then switched to 10%S + T3 for another two weeks. At the end of 4 weeks, the constructs were processed for analysis by indirect-immunofluorescence (IF) and transmission electron microscopy (TEM). Different collagens that are normally present in healthy corneas in vivo, such as Type I and V, as well as Type III, which is a fibrotic indicator, were examined. In addition, we examined smooth muscle actin (SMA), a marker of myofibroblasts, and thrombospondin-1 (TSP-1), a multifunctional matrix protein known to activate the latent complex of TGF-β and appear upon wounding in vivo. Our data showed high expression of collagens type I and V under all conditions throughout the 3D constructs; however, type III and SMA expression were higher in the constructs that were stimulated with T1 and reduced to almost nothing in the Rescue samples. A similar pattern was seen with TSP-1, where TSP-1 expression following "rescue" was decreased considerably. Overall, this data is in agreement with our previous observations that T3 has a significant non-fibrotic effect on HCFs, and presents a novel model for the "rescue" of both cellular and matrix fibrotic components with a single growth factor.

Indexed as

ActinsAntibodiesCells, CulturedCorneal DiseasesCorneal KeratocytesExtracellular MatrixFibrosisFluorescent Antibody Technique, IndirectHumansMicroscopy, Electron, TransmissionTransforming Growth Factor beta3ActinsAntibodiesTransforming Growth Factor beta3corneal fibrosiscorneal stromaextracellular matrixmyofibroblastTGF-β3

Identifiers

PMID24800655
PMCPMC4065812
OpenAlexW2087820356

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.